Bioscibex, Inkocell Therapeutics, and OrthoSens Supported By Venture Kick

Bioscibex, Inkocell Therapeutics, and OrthoSens were selected at Venture Kick’s second financial and entrepreneurial support stage and get each a CHF 40’000 support.

These three Swiss Health Valley startups reshape biopharma, oncology, and orthopedic recovery. Bioscibex, Inkocell Therapeutics, and OrthoSens have progressed to the second stage of Venture Kick, securing support to drive their innovations forward.

• Bioscibex is revolutionizing biologics manufacturing with a single-use bioreactor that slashes process steps from 7 to 2—cutting costs, reducing contamination risk, and simplifying production. The EPFL spin-off, led by Chloé Albietz and François Carruzzo, targets a USD 4.5M market. Venture Kick funds will help build their beta prototype.
  More: bioscibex.com

• Inkocell Therapeutics is developing a curative therapy for cancer survivors suffering from cardiac fibrosis—a life-threatening side effect of treatment. Using engineered NK cells with a patented receptor, their technology has broader potential for autoimmune and fibrotic diseases. The EPFL-based startup will use the funding to advance IP and regulatory planning.

• OrthoSens is redefining orthopedic recovery with battery-free sensor implants and an app that creates a continuous “recovery movie.” This real-time insight enables earlier interventions and better outcomes. With support from Venture Kick, they’ll develop demonstrators and marketing assets to engage clinical and industrial partners in a USD 56B+ market.

➡️ Source: Venture Kick
📸 Bioscibex: CEO Chloé Albietz & CTO François Carruzzo | Inkocell Therapeutics: CEO Mathieu Girardin & CSO Angela Madurga Alonso | OrthoSens: CEO Gwenael Hannema, Lead R&D Oleg Kotsur, Strategic Advisor Philippe Etter, and KOL Prof. Alex Alfieri